

Atsushi Hiraoka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8133285/publications.pdf>

Version: 2024-02-01

141
papers

5,276
citations

117453

34
h-index

106150

65
g-index

141
all docs

141
docs citations

141
times ranked

4249
citing authors

#	ARTICLE	IF	CITATIONS
1	JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. <i>Liver Cancer</i> , 2014, 3, 458-468.	4.2	512
2	Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. <i>Liver Cancer</i> , 2021, 10, 181-223.	4.2	307
3	Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSCJ Criteria 2014 Update. <i>Oncology</i> , 2014, 87, 22-31.	0.9	216
4	Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. <i>Liver Cancer</i> , 2017, 6, 325-336.	4.2	202
5	Usefulness of albuminâ€“bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1031-1036.	1.4	198
6	Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. <i>Liver Cancer</i> , 2017, 6, 204-215.	4.2	159
7	Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. <i>Liver Cancer</i> , 2019, 8, 121-129.	4.2	159
8	Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in realâ€“world conditionsâ€”Multicenter analysis. <i>Cancer Medicine</i> , 2019, 8, 3719-3728.	1.3	131
9	Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study. <i>Cancers</i> , 2019, 11, 952.	1.7	114
10	Efficacy of branched-chain amino acid supplementation and walking exercise for preventing sarcopenia in patients with liver cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 1416-1423.	0.8	113
11	Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis. <i>Digestive Diseases</i> , 2017, 35, 602-610.	0.8	113
12	Clinical features of lenvatinib for unresectable hepatocellular carcinoma in realâ€“world conditions: Multicenter analysis. <i>Cancer Medicine</i> , 2019, 8, 137-146.	1.3	112
13	Percutaneous ultrasound-guided radiofrequency ablation of hepatocellular carcinoma with artificially induced pleural effusion and ascites. <i>Journal of Gastroenterology</i> , 2007, 42, 306-311.	2.3	95
14	Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure. <i>Journal of Gastroenterology</i> , 2005, 40, 52-56.	2.3	92
15	Muscle atrophy as pre-sarcopenia in Japanese patients with chronic liver disease: computed tomography is useful for evaluation. <i>Journal of Gastroenterology</i> , 2015, 50, 1206-1213.	2.3	90
16	Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients. <i>Liver Cancer</i> , 2019, 8, 312-325.	4.2	88
17	Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenib. <i>Hepatology Research</i> , 2017, 47, 558-565.	1.8	82
18	Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis. <i>Hepatology Research</i> , 2019, 49, 111-117.	1.8	81

#	ARTICLE	IF	CITATIONS
19	Virtual Sonographic Radiofrequency Ablation of Hepatocellular Carcinoma Visualized on CT but Not on Conventional Sonography. <i>American Journal of Roentgenology</i> , 2006, 186, S255-S260.	1.0	73
20	Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma. <i>Oncology</i> , 2019, 97, 277-285.	0.9	66
21	Radiofrequency ablation therapy for hepatocellular carcinoma in elderly patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 403-407.	1.4	57
22	Sarcopenia and two types of presarcopenia in Japanese patients with chronic liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 940-947.	0.8	57
23	Expression of CD163 in the liver of patients with viral hepatitis. <i>Pathology Research and Practice</i> , 2005, 201, 379-384.	1.0	52
24	Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. <i>Liver International</i> , 2020, 40, 968-976.	1.9	51
25	Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan. <i>Journal of Gastroenterology</i> , 2018, 53, 119-128.	2.3	49
26	Amino acid imbalance in patients with chronic liver diseases. <i>Hepatology Research</i> , 2010, 40, 393-398.	1.8	45
27	Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. <i>Liver International</i> , 2021, 41, 1389-1397.	1.9	45
28	Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matching. <i>Hepatology Research</i> , 2020, 50, 75-83.	1.8	44
29	Complications after Radiofrequency Ablation for Hepatocellular Carcinoma: A Multicenter Study Involving 9,411 Japanese Patients. <i>Liver Cancer</i> , 2020, 9, 50-62.	4.2	44
30	Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience. <i>Cancer Reports</i> , 2022, 5, e1464.	0.6	43
31	Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B. <i>Journal of Hepatology</i> , 2017, 66, 521-527.	1.8	41
32	Role of hepatic resection in patients with intermediate-stage hepatocellular carcinoma: A multicenter study from Japan. <i>Cancer Science</i> , 2017, 108, 1414-1420.	1.7	40
33	Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1066-1073.	1.4	40
34	Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma. <i>Oncology</i> , 2019, 97, 334-340.	0.9	39
35	Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib. <i>Liver Cancer</i> , 2020, 9, 73-83.	4.2	37
36	Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade. <i>Oncology</i> , 2016, 91, 153-161.	0.9	36

#	ARTICLE	IF	CITATIONS
37	EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis. <i>Liver Cancer</i> , 2020, 9, 734-743.	4.2	35
38	Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study. <i>Hepatology International</i> , 2022, 16, 1150-1160.	1.9	35
39	Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 293.	1.7	34
40	Efficacy of radiofrequency ablation therapy compared to surgical resection in 164 patients in Japan with single hepatocellular carcinoma smaller than 3 cm, along with report of complications. <i>Hepato-Gastroenterology</i> , 2008, 55, 2171-4.	0.5	34
41	Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice. <i>Hepatology Research</i> , 2022, 52, 773-783.	1.8	34
42	Clinical translation in the treatment of hepatocellular carcinoma following the introduction of contrast-enhanced ultrasonography with Sonazoid. <i>Oncology Letters</i> , 2010, 1, 57-61.	0.8	33
43	New contrast enhanced ultrasonography agent: Impact of Sonazoid on radiofrequency ablation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 616-618.	1.4	33
44	Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study. <i>Hepatology Research</i> , 2021, 51, 1229-1241.	1.8	33
45	Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. <i>Oncology</i> , 2015, 89, 167-174.	0.9	31
46	Prognosis and therapy for ruptured hepatocellular carcinoma: Problems with staging and treatment strategy. <i>European Journal of Radiology</i> , 2015, 84, 366-371.	1.2	31
47	ALBI Score as a Novel Tool in Staging and Treatment Planning for Hepatocellular Carcinoma: Advantage of ALBI Grade for Universal Assessment of Hepatic Function. <i>Liver Cancer</i> , 2017, 6, 377-379.	4.2	30
48	Transcatheter Arterial Chemoembolization With or Without Radiofrequency Ablation: Outcomes in Patients With Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma. <i>American Journal of Roentgenology</i> , 2018, 210, 891-898.	1.0	30
49	Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. <i>Scientific Reports</i> , 2021, 11, 16663.	1.6	30
50	Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan. <i>Liver Cancer</i> , 2019, 8, 403-411.	4.2	28
51	Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies. <i>Liver Cancer</i> , 2020, 9, 41-49.	4.2	28
52	Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1812-1819.	1.4	28
53	Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 698-706.	0.8	27
54	Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 42-47.	0.6	25

#	ARTICLE	IF	CITATIONS
55	The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study. <i>Hepatology International</i> , 2020, 14, 225-238.	1.9	25
56	Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria. <i>Journal of Gastroenterology</i> , 2021, 56, 90-100.	2.3	25
57	Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC stage patients classified as beyond up to seven criteria – Multicenter analysis. <i>Hepatology Research</i> , 2022, 52, 308-316.	1.8	25
58	Does first-line treatment have prognostic impact for unresectable HCC? Atezolizumab plus bevacizumab versus lenvatinib. <i>Cancer Medicine</i> , 2023, 12, 325-334.	1.3	25
59	Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases. <i>Oncology</i> , 2017, 93, 120-126.	0.9	24
60	Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma. <i>Oncology</i> , 2020, 98, 295-302.	0.9	24
61	Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: A multicenter study from Japan. <i>Hepatology Research</i> , 2016, 46, 734-742.	1.8	23
62	Easy surveillance of muscle volume decline in chronic liver disease patients using finger yubiaki test. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 347-354.	2.9	23
63	Can L-carnitine supplementation and exercise improve muscle complications in patients with liver cirrhosis who receive branched-chain amino acid supplementation?. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 878-884.	0.8	23
64	Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 855-861.	1.4	23
65	Huge Pancreatic Acinar Cell Carcinoma with High Levels of AFP and Fucosylated AFP (AFP-L3). <i>Internal Medicine</i> , 2012, 51, 1341-1349.	0.3	22
66	Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis. <i>Hepatology Research</i> , 2021, 51, 201-215.	1.8	22
67	Impact of muscle volume and muscle function decline in patients undergoing surgical resection for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1271-1276.	1.4	21
68	Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after Direct Acting Antivirals: multicenter analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 436-441.	1.4	21
69	Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma. <i>Gastroenterology Report</i> , 2021, 9, 133-138.	0.6	21
70	Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis. <i>Cancer Medicine</i> , 2022, 11, 3796-3808.	1.3	21
71	Treatment of hepatocellular carcinoma during the COVID-19 outbreak: The Working Group report of JAMT-HCC. <i>Hepatology Research</i> , 2020, 50, 1004-1014.	1.8	20
72	A better method for assessment of hepatic function in hepatocellular carcinoma patients treated with radiofrequency ablation: Usefulness of albumin-bilirubin grade. <i>Hepatology Research</i> , 2018, 48, E61-E67.	1.8	19

#	ARTICLE	IF	CITATIONS
73	Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 646.	1.7	19
74	Trends and Efficacy of Interferon-Free Anti-hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz185.	0.4	18
75	Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. <i>Liver International</i> , 2021, 41, 2997-3008.	1.9	18
76	Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis. <i>Hepatology Research</i> , 2022, 52, 462-470.	1.8	18
77	Ultrasonography screening for hepatocellular carcinoma in Japanese patients with diabetes mellitus. <i>Journal of Diabetes</i> , 2016, 8, 640-646.	0.8	17
78	Importance of screening for synchronous malignant neoplasms in patients with hepatocellular carcinoma: impact of ^{FDG PET}/^{CT}. <i>Liver International</i> , 2013, 33, 1085-1091.	1.9	16
79	Local recurrence of hepatocellular carcinoma in the tumor blood drainage area following radiofrequency ablation. <i>Molecular and Clinical Oncology</i> , 2014, 2, 182-186.	0.4	16
80	Prediction of risk of falls based on handgrip strength in chronic liver disease patients living independently. <i>Hepatology Research</i> , 2019, 49, 823-829.	1.8	16
81	Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study. <i>Infectious Diseases and Therapy</i> , 2020, 9, 851-866.	1.8	16
82	Prognosis following transcatheter arterial embolization for 121 patients with unresectable hepatocellular carcinoma with or without a history of treatment. <i>World Journal of Gastroenterology</i> , 2006, 12, 2075.	1.4	16
83	Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study. <i>Liver Cancer</i> , 2022, 11, 527-539.	4.2	16
84	Hepatic Encephalopathy Due to Intrahepatic Portosystemic Venous Shunt Successfully Treated by Interventional Radiology. <i>Internal Medicine</i> , 2005, 44, 212-216.	0.3	15
85	Effects of long-term entecavir treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients. <i>Hepatology International</i> , 2016, 10, 320-327.	1.9	15
86	Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. <i>Hepatology Research</i> , 2021, 51, 880-889.	1.8	15
87	Relative changes in handgrip strength and skeletal muscle volume in patients with chronic liver disease over a 2-year observation period. <i>Hepatology Research</i> , 2018, 48, 502-508.	1.8	14
88	Muscle volume loss a prognostic factor for death in liver cirrhosis patients and special relationship to portal hypertension. <i>Hepatology Research</i> , 2018, 48, E354-E359.	1.8	14
89	Modified technique for determining therapeutic response to radiofrequency ablation therapy for hepatocellular carcinoma using US-volume system. <i>Oncology Reports</i> , 2010, 23, 493-7.	1.2	14
90	¹⁸ F-FDG-PET/CT predicts the distribution of microsatellite lesions in hepatocellular carcinoma. <i>Molecular and Clinical Oncology</i> , 2014, 2, 798-804.	0.4	13

#	ARTICLE	IF	CITATIONS
91	Zinc deficiency as an independent prognostic factor for patients with early hepatocellular carcinoma due to hepatitis virus. <i>Hepatology Research</i> , 2020, 50, 92-100.	1.8	13
92	Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1229-1237.	1.4	13
93	Impact of modified albuminâ€“bilirubin grade on survival in patients with HCC who received lenvatinib. <i>Scientific Reports</i> , 2021, 11, 14474.	1.6	13
94	Clinical features of liver cirrhosis patients with muscle cramping: a multicenter study. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1557-1562.	0.8	12
95	Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma. <i>Internal Medicine</i> , 2019, 58, 791-795.	0.3	12
96	What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?. <i>Liver Cancer</i> , 2021, 10, 115-125.	4.2	12
97	Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response. <i>Hepatology Communications</i> , 2021, 5, 1290-1299.	2.0	12
98	Firstâ€“line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study. <i>Cancer Medicine</i> , 2021, 10, 8530-8541.	1.3	12
99	SARCâ€“F combined with a simple tool for assessment of muscle abnormalities in outpatients with chronic liver disease. <i>Hepatology Research</i> , 2020, 50, 502-511.	1.8	11
100	Abdominal Imaging Findings of a Patient with Hepatocellular Carcinoma Associated with Glycogen Storage Disease Type 1a. <i>Internal Medicine</i> , 2011, 50, 2317-2322.	0.3	10
101	Utility of the SARC-F Questionnaire for Sarcopenia Screening in Patients with Chronic Liver Disease: A Multicenter Cross-Sectional Study in Japan. <i>Journal of Clinical Medicine</i> , 2021, 10, 3448.	1.0	10
102	Efficacy of lamivudine therapy for decompensated liver cirrhosis due to hepatitis B virus with or without hepatocellular carcinoma. <i>Oncology Reports</i> , 2005, 13, 1159-63.	1.2	10
103	Association of Albumin-Bilirubin Grade and Sequential Treatment with Standard Systemic Therapies for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study Using a Japanese Administrative Database. <i>Drugs - Real World Outcomes</i> , 2021, 8, 301-314.	0.7	9
104	Risk factors for death in 224 cases of hepatocellular carcinoma after transcatheter arterial chemoembolization. <i>Hepato-Gastroenterology</i> , 2009, 56, 213-7.	0.5	9
105	<p>Japanese patient preferences regarding intermediate to advanced hepatocellular carcinoma treatments</p>. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 637-647.	0.8	8
106	Combination of Resection and Ablative Treatment for Hepatocellular Carcinoma: Usefulness of Complementary Radiofrequency Ablation. <i>Oncology</i> , 2019, 96, 242-251.	0.9	8
107	Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 420-432.	0.6	8
108	Is there a survival benefit in interventional radiology for hepatocellular carcinoma in patients with Child-Pugh C liver cirrhosis?: A multicenter study. <i>Hepatology Research</i> , 2016, 46, 521-528.	1.8	7

#	ARTICLE	IF	CITATIONS
109	A Possible Case of Hepatitis due to Hypereosinophilic Syndrome. <i>Internal Medicine</i> , 2016, 55, 1453-1458.	0.3	7
110	Easy clinical predictor for low BCAA to tyrosine ratio in chronic liver disease patients with hepatocellular carcinoma: Usefulness of ALBI score as nutritional prognostic marker. <i>Cancer Medicine</i> , 2021, 10, 3584-3592.	1.3	7
111	Sequential therapy including regorafenib for unresectable hepatocellular carcinoma: Effect of early relative changes in hepatic functional reserve after regorafenib administration on prognosis. <i>Hepatology Research</i> , 2021, 51, 1219-1228.	1.8	7
112	Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis. <i>Hepatology Research</i> , 2022, 52, 235-246.	1.8	7
113	Predicting Complications following Surgical Resection of Hepatocellular Carcinoma Using Newly Developed Neo-Glasgow Prognostic Score with ALBI Grade: Comparison of Open and Laparoscopic Surgery Cases. <i>Cancers</i> , 2022, 14, 1402.	1.7	7
114	Utility of FIB4-T as a Prognostic Factor for Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 203.	1.7	6
115	Recent Trends of Japanese Hepatocellular Carcinoma due to HCV in Aging Society. <i>Hepato-Gastroenterology</i> , 2011, 59, 1893-5.	0.5	6
116	Chronological change in serum albumin as a prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albumin-bilirubin score (ALBS grade). <i>Journal of Gastroenterology</i> , 2022, 57, 581-586.	2.3	6
117	Clinical features of hemodialysis patients treated for hepatocellular carcinoma: Comparison between resection and radiofrequency ablation. <i>Molecular and Clinical Oncology</i> , 2017, 6, 455-461.	0.4	5
118	Early detection of hepatocellular carcinoma in patients with diabetes mellitus. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 877-881.	0.8	5
119	Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis. <i>Oncology</i> , 2021, 99, 518-527.	0.9	5
120	The prognosis of elderly patients with hepatocellular carcinoma: A multicenter 19-year experience in Japan. <i>Cancer Medicine</i> , 2023, 12, 345-357.	1.3	5
121	Prognostic Scoring System for radiofrequency ablation: Usefulness of Albumin-bilirubin (ALBI)-grade. <i>Acta Hepatologica Japonica</i> , 2016, 57, 312-319.	0.0	4
122	C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. <i>Scientific Reports</i> , 2022, 12, 8421.	1.6	4
123	Exacerbation of psoriasis vulgaris by sorafenib treatment for hepatocellular carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 891-895.	0.4	3
124	The effects of diuretic use and the presence of ascites on muscle cramps in patients with cirrhosis: a nationwide study. <i>Journal of Gastroenterology</i> , 2020, 55, 868-876.	2.3	3
125	Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era. <i>Oncology</i> , 2022, 100, 65-73.	0.9	3
126	Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 857-864.	0.8	3

#	ARTICLE	IF	CITATIONS
127	Carcinoma with shared pathologic characteristics of both hepatocellular carcinoma and cholangiocarcinoma. <i>Current Therapeutic Research</i> , 2005, 66, 589-597.	0.5	2
128	FDG positron emission tomography/computed tomography findings for the prediction of early recurrence of hepatocellular carcinoma after surgical resection. <i>Experimental and Therapeutic Medicine</i> , 2010, 1, 829-832.	0.8	2
129	Clinical Role of Newly Developed ALBI and mALBI Grades for Treatment of Hepatocellular Carcinoma. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 7178.	1.3	2
130	Efficacy of lamivudine therapy for decompensated liver cirrhosis due to hepatitis B virus with or without hepatocellular carcinoma. <i>Oncology Reports</i> , 0, , .	1.2	2
131	Diagnostic value of sonazoid for hepatic metastasis: comparison with FDG PET/CT. <i>Hepato-Gastroenterology</i> , 2010, 57, 1237-40.	0.5	2
132	Comparison of the New Neo-Glasgow Prognostic Score Based on the Albumin-Bilirubin Grade with Currently Used Nutritional Indices for Prognostic Prediction following Surgical Resection of Hepatocellular Carcinoma: A Multicenter Retrospective Study in Japan. <i>Cancers</i> , 2022, 14, 2091.	1.7	2
133	Clinical features of fatty liver in nonobese Japanese without regular alcohol intake. <i>Diabetology International</i> , 2015, 6, 60-65.	0.7	1
134	Importance of Screening for Esophagogastric Varices in Na ⁺ -ve Hepatocellular Carcinoma Patients within Milan Criteria: Indicator for Liver Transplantation. <i>Digestive Surgery</i> , 2017, 34, 429-435.	0.6	1
135	Simple method with tumor markers for predicting prognosis following transcatheter arterial chemo-embolization for switching to next therapy in intermediate hepatocellular carcinoma: multi-center analysis. <i>Acta Hepatologica Japonica</i> , 2017, 58, 329-337.	0.0	1
136	Factors Related to Sleeping Disorder Due to Pruritus in Patients with Chronic Liver Disease. <i>Internal Medicine</i> , 2021, 60, 3195-3203.	0.3	1
137	Simple scoring index for early detection of non-B, non-C hepatocellular carcinoma in patients with diabetes mellitus. <i>Acta Hepatologica Japonica</i> , 2019, 60, 156-158.	0.0	1
138	Hepatic resection assisted by ablative therapy for advanced hepatocellular carcinoma. <i>Hepato-Gastroenterology</i> , 2011, 58, 955-9.	0.5	1
139	Shorter pruritus period and milder disease stage are associated with response to nalfurafine hydrochloride in patients with chronic liver disease. <i>Scientific Reports</i> , 2022, 12, 7311.	1.6	1
140	Safety and effectiveness of sorafenib in elderly patients with HCC. <i>Acta Hepatologica Japonica</i> , 2015, 56, 369-372.	0.0	0
141	Ultrasonography surveillance improves prognosis of patients with hepatocellular carcinoma. <i>Molecular and Clinical Oncology</i> , 2019, 11, 325-330.	0.4	0